W/O regard to the other drug, I'll say I agree with you about being the new standard of care. The drug has been the same drug as it was when Kazia licensed it, however. Considering the dearth of drugs for GBM, Paxalisib did not need to be "rushed" to market. The likelihood of anything being better was very small.
The AGILE trial saves time and money due to it's configuration. The AGILE team wanted Pax to participate. Remember when they said they would be doing the AGILE trial? They had already been corresponding with the AGILE folks for 6 months prior to the announcement.
Alternatively, acceding to your "rushed" judgement, why would it not be more beneficial to patients (and the company) to be in a hurry?
Add to My Watchlist
What is My Watchlist?